(Q46102734)

19 December 2017

title

MF59 emulsion is an effective delivery system for a synthetic TLR4 agonist (E6020). (English)

1 reference

19 December 2017

0 references

8

1 reference

19 December 2017

author name string

Barbara C Baudner

1

1 reference

19 December 2017

Vanessa Ronconi

2

1 reference

19 December 2017

Daniele Casini

3

1 reference

19 December 2017

Marco Tortoli

4

1 reference

19 December 2017

Jina Kazzaz

5

1 reference

19 December 2017

Manmohan Singh

6

1 reference

19 December 2017

Lynn D Hawkins

7

1 reference

19 December 2017

Derek T O'Hagan

9

1 reference

19 December 2017

publication date

3 March 2009

1 reference

19 December 2017

published in

Pharmaceutical Research

1 reference

19 December 2017

volume

26

1 reference

19 December 2017

issue

6

1 reference

19 December 2017

page(s)

1477-1485

1 reference

19 December 2017

Age-associated change in the frequency of memory CD4+ T cells impairs long term CD4+ T cell responses to influenza vaccine

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11095-009-9859-5

Cell-mediated protection in influenza infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-009-9859-5

Improving vaccine delivery using novel adjuvant systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-009-9859-5

The adjuvants aluminum hydroxide and MF59 induce monocyte and granulocyte chemoattractants and enhance monocyte differentiation toward dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-009-9859-5

Tumor necrosis factor alpha exerts powerful anti-influenza virus effects in lung epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-009-9859-5

Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-009-9859-5

A recombinant glycoprotein vaccine for herpes simplex virus type 2: safety and immunogenicity [corrected]

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-009-9859-5

Toll-like receptors: networking for success.

21 January 2018

1 reference

12 December 2020

The perfect mix: recent progress in adjuvant research

1 reference

12 December 2020

Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice.

1 reference

12 December 2020

Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza.

1 reference

12 December 2020

Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only

1 reference

12 December 2020

A preliminary evaluation of alternative adjuvants to alum using a range of established and new generation vaccine antigens

1 reference

12 December 2020

A novel class of endotoxin receptor agonists with simplified structure, toll-like receptor 4-dependent immunostimulatory action, and adjuvant activity

1 reference

12 December 2020

Correlates of immune protection in HIV-1 infection: what we know, what we don't know, what we should know

1 reference

12 December 2020

GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives

1 reference

12 December 2020

Impact of immunization with glycoprotein D2/AS04 on herpes simplex virus type 2 shedding into the genital tract in guinea pigs that become infected

1 reference

12 December 2020

HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells

1 reference

12 December 2020

Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. Chiron HSV Vaccine Study Group

1 reference

12 December 2020

MF59-adjuvanted vaccines: increased immunogenicity with an optimal safety profile

1 reference

12 December 2020

Distribution of adjuvant MF59 and antigen gD2 after intramuscular injection in mice

1 reference

12 December 2020

Effect of CpG oligodeoxynucleotides on the immunogenicity of Pfs25, a Plasmodium falciparum transmission-blocking vaccine antigen

1 reference

12 December 2020

Molecular and cellular signatures of human vaccine adjuvants.

1 reference

12 December 2020

Alum adjuvanticity: unraveling a century old mystery

1 reference

12 December 2020

Safety and immunogenicity of nonadjuvanted and MF59-adjuvanted influenza A/H9N2 vaccine preparations.

1 reference

12 December 2020

Regulation of dendritic cell function through Toll-like receptors

1 reference

12 December 2020

New hepatitis B vaccine formulated with an improved adjuvant system

1 reference

12 December 2020

Antibody response to influenza vaccination in the elderly: a quantitative review

1 reference

12 December 2020

Local and systemic cytokine responses during experimental human influenza A virus infection. Relation to symptom formation and host defense

1 reference

12 December 2020

E6020: a synthetic Toll-like receptor 4 agonist as a vaccine adjuvant

1 reference

12 December 2020

Serologic studies of acute respiratory infections in military personnel

1 reference

12 December 2020

Vaccination in humans generates broad T cell cytokine responses

1 reference

12 December 2020

Novel synthetic LPS receptor agonists boost systemic and mucosal antibody responses in mice.

1 reference

12 December 2020

Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle

1 reference

12 December 2020

Safety of 2 recombinant human immunodeficiency virus type 1 (HIV-1) envelope vaccines in neonates born to HIV-1-infected women

1 reference

12 December 2020

Lymphoproliferative Responses to Recombinant HIV‐1 Envelope Antigens in Neonates and Infants Receiving gp120 Vaccines

1 reference

12 December 2020

Encapsulation of the immune potentiators MPL and RC529 in PLG microparticles enhances their potency

1 reference

12 December 2020

A new MF59-adjuvanted influenza vaccine enhances the immune response in the elderly with chronic diseases: results from an immunogenicity meta-analysis

1 reference

12 December 2020

Human immunodeficiency virus type 1 (HIV-1) gp120-specific antibodies in neonates receiving an HIV-1 recombinant gp120 vaccine

1 reference

12 December 2020

Influenza and the challenge for immunology

1 reference

12 December 2020

Tumour necrosis factors alpha and beta inhibit virus replication and synergize with interferons

1 reference

12 December 2020

Enhancement of antigen-specific immunity via the TLR4 ligands MPL adjuvant and Ribi.529.

1 reference

12 December 2020

1 reference

12 December 2020

A direct comparison of human papillomavirus type 16 L1 particles reveals a lower immunogenicity of capsomeres than viruslike particles with respect to the induced antibody response

1 reference

12 December 2020

Immunogenicity of a recombinant human cytomegalovirus gB vaccine in seronegative toddlers

1 reference

12 December 2020

Toll-like receptor control of the adaptive immune responses

1 reference

12 December 2020

Synergistic adjuvant activity of immunostimulatory DNA and oil/water emulsions for immunization with HIV p55 gag antigen

1 reference

12 December 2020

Recent advances in the discovery and delivery of vaccine adjuvants

1 reference

12 December 2020

Boosting immunity to influenza H5N1 with MF59-adjuvanted H5N3 A/Duck/Singapore/97 vaccine in a primed human population

1 reference

12 December 2020

A CpG-containing oligodeoxynucleotide as an efficient adjuvant counterbalancing the Th1/Th2 immune response in diphtheria-tetanus-pertussis vaccine

1 reference

12 December 2020

Safety and immunogenicity of MF59-adjuvanted influenza vaccine in the elderly

1 reference

12 December 2020

A randomized, controlled study in adults of the immunogenicity of a novel hepatitis B vaccine containing MF59 adjuvant

1 reference

12 December 2020

Immunogenicity and safety of an adjuvanted hepatitis B vaccine in pre-hemodialysis and hemodialysis patients

1 reference

12 December 2020

MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection.

1 reference

12 December 2020

Improving vaccines by incorporating immunological coadjuvants

1 reference

12 December 2020

Evaluation of systemic and mucosal anti-HPV16 and anti-HPV18 antibody responses from vaccinated women

1 reference

12 December 2020

T cell responses are better correlates of vaccine protection in the elderly

1 reference

12 December 2020

Functional signatures of protective antiviral T-cell immunity in human virus infections.

1 reference

12 December 2020

10.1007/S11095-009-9859-5

Identifiers

DOI

1 reference

19 December 2017

release_wxrpyzbzdnbkrdcgwbg3fdygte

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/wxrpyzbzdnbkrdcgwbg3fdygte

24 November 2022

mapped directly with Wikidata item

1 reference

19 December 2017